Midterm outcomes of aortic root surgery in patients with Marfan syndrome: A prospective, multicenter, comparative study

The objective of this study was to compare midterm outcomes of aortic valve-replacing root replacement (AVR) and aortic valve-sparing root replacement (AVS) operations in patients with Marfan syndrome. Patients who met strict Ghent diagnostic criteria for Marfan syndrome and who underwent either AVR...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of thoracic and cardiovascular surgery 2023-05, Vol.165 (5), p.1790-1799.e12
Hauptverfasser: Coselli, Joseph S., Volguina, Irina V., LeMaire, Scott A., Connolly, Heidi M., Sundt, Thoralf M., Milewicz, Dianna M., Dietz, Harry C., Amarasekara, Hiruni S., Green, Susan Y., Zhang, Qianzi, Schaff, Hartzell V., Miller, D. Craig
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The objective of this study was to compare midterm outcomes of aortic valve-replacing root replacement (AVR) and aortic valve-sparing root replacement (AVS) operations in patients with Marfan syndrome. Patients who met strict Ghent diagnostic criteria for Marfan syndrome and who underwent either AVR or AVS between March 1, 2005 and December 31, 2010 were enrolled in a 3-year follow-up prospective, multicenter, international registry study; the study was subsequently amended to include 20-year follow-up. Enrollees were followed clinically and echocardiographically. Of the 316 patients enrolled, 77 underwent AVR and 239 underwent AVS; 214 gave reconsent for 20-year follow-up. The median clinical follow-up time for surviving patients was 64 months (interquartile range, 42-66 months). Survival rates for the AVR and AVS groups were similar at 88.2% ± 4.4% and 95.0% ± 1.5%, respectively (P = .1). Propensity score-adjusted competing risk modeling showed associations between AVS and higher cumulative incidences of major adverse valve-related events, valve-related morbidity, combined structural valve deterioration and nonstructural valve dysfunction, and aortic regurgitation ≥2+ (all P 
ISSN:0022-5223
1097-685X
1097-685X
DOI:10.1016/j.jtcvs.2021.08.064